The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
Abstract
Purpose: To determine the safety, dose‐limiting toxicity and maximum tolerated dose (MTD) of the novel hydroxamate histone deacetylase inhibitor belinostat (PXD101) in patients with advanced hematological neoplasms. Patients and methods: Sequential dose‐escalating cohorts of three to six patients with hematological malignancies received belinostat administered as a 30‐min i.v. infusion on days 1–5 of a 21‐d cycle. Experience from a parallel dose‐finding study in patients with solid tumors influenced the selection of the final dose. Results: Sixteen patients received belinostat at one of three dose levels: 600 mg/m 2/d (three patients), 900 mg/m 2/d (three patients) and 1000 mg/m 2/d (10 patients), the dose determined to be the MTD in a phase I solid tumor study [Steele et al. (2008) Clin Cancer Res, 14, 804–10]. The most common treatment‐related adverse events (all grades) were nausea (50%), vomiting (31%), fatigue (31%) and flushing (31%). No grade 3 or 4 hematological toxicity compared with baseline occurred except one case of grade 3 lymphopenia. There were two related grade 4 adverse events of renal failure observed. Both events occurred in patients with multiple myeloma and had similar characteristics, i.e. an acute episode of decrease in renal function (pre‐existing nephropathy in one patient), with a metabolic profile and decrease in tumor burden consistent with tumor lysis syndrome. No other related grade 4 events were noted. The only related grade 3 events noticed in more than one patient were fatigue and neurological symptoms (one patient had status epilepticus in association with uremia and one patient had paresthesia), all other related grade 3 events occurred in single patients. No cardiac events were noted. No complete or partial remissions were noted in these heavily pre‐treated (median of four prior regimens) patients. However, five patients, including two patients with diffuse large‐cell lymphoma [including one patient with transformed chronic myelomcytic leukaemia (CLL)], two patients with CLL and one patient with multiple myeloma, achieved disease stabilization in of two to nine treatment cycles. Conclusions: Intravenous belinostat at 600, 900 and 1000 mg/m 2/d is well tolerated by patients with hematological malignancies. The study was carried out in parallel to a similar dose‐finding study in patients with solid tumors, in which the MTD was determined to be 1000 mg/m 2/d days 1–5 in a 21‐d cycle. This dose can also be recommended for phase II studies in patients with hematological neoplasms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 4×
“Many inhibitors of apoptosis are repressed by HDAC inhibitors (HDACi) and pro-apoptotic genes are activated (1, 5).”
BackgroundInfluentialInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Cited by
O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.2782 · Cited by 555
Self-citationNovel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-5 · Cited by 425
Clinical Toxicities of Histone Deacetylase Inhibitors
Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals · doi:10.3390/ph3092751 · Cited by 386
“Anorexia (up to 20% grade 3–4 in phase II trials) and dysgeusia can impact patients receiving long-term therapy [4,7,10].”
BackgroundClinical Studies of Histone Deacetylase Inhibitors
Prince, H. M., Bishton, M. J., & Harrison, S. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2785 · Cited by 356
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Metadata
- Authors
- Gimsing, P., Hansen, M., Knudsen, L. M., Knoblauch, P., Christensen, I. J., Ooi, C. E., & Buhl‐Jensen, P.
- Venue
- European Journal of Haematology
- Publisher
- Wiley
- Published
- 2008-08-07
- Volume
- 81
- Issue
- 3
- Pages
- 170-176
- ISSN
- 0902-4441 (ISSN-L)
- 1600-0609
- OpenAlex
- W1991376723
- Cited by
- 160
- References
- 2
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. https://app.cochat.ai/papers/10.1111/j.1600-0609.2008.01102.x
- The paper
- Gimsing, P., Hansen, M., Knudsen, L. M., Knoblauch, P., Christensen, I. J., Ooi, C. E., & Buhl‐Jensen, P. (2008). A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. European Journal of Haematology. https://doi.org/10.1111/j.1600-0609.2008.01102.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.